$TSVT
2seventy bio, Inc. Stock $tsvt

$tsvt Overview Financials Valuation SEC Filings Company Website

2022 Q4 Form 10-Q Financial Statement

#000186078222000067 Filed on November 07, 2022

Income Statement

Concept	2022 Q4	2022 Q3	2021 Q3
Revenue	$56.18M	$13.41M	$19.26M
YoY Change	250.36%	-30.37%	4.46%
Cost Of Revenue	$15.33M	$377.0K	$320.0K
YoY Change	3674.63%	17.81%	-75.72%
Gross Profit	$40.85M	$13.03M	$18.94M
YoY Change	161.4%	-31.19%	10.64%
Gross Profit Margin	72.72%	97.19%	98.34%
Selling, General & Admin	$18.70M	$19.61M	$23.00M
YoY Change	-23.61%	-14.72%	4.03%
% of Gross Profit	45.78%	150.49%	121.43%
Research & Development	$49.31M	$61.74M	$61.13M
YoY Change	-17.18%	0.99%	-15.39%
% of Gross Profit	120.71%	473.79%	322.81%
Depreciation & Amortization	$2.325M	$2.377M	$3.500M
YoY Change	-34.23%	-32.09%	45.83%
% of Gross Profit	5.69%	18.24%	18.48%
Operating Expenses	$68.06M	$81.35M	$84.13M
YoY Change	-18.97%	-3.3%	-10.84%
Operating Profit	-$27.21M	-$68.37M	-$65.24M
YoY Change	-60.2%	4.8%	-14.63%
Interest Expense	$1.491M	$1.113M	$0.00
YoY Change	1594.32%
% of Operating Profit
Other Income/Expense, Net	$2.561M	-$624.0K	$5.237M
YoY Change	-64.95%	-111.92%	20.7%
Pretax Income	-$23.16M	-$67.88M	-$60.00M
YoY Change	-62.02%	13.13%	-16.75%
Income Tax	-$17.00K	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$23.14M	-$67.88M	-$60.00M
YoY Change	-62.05%	13.13%	-16.75%
Net Earnings / Revenue	-41.2%	-506.26%	-311.58%
Basic Earnings Per Share		-$1.76	-$2.57
Diluted Earnings Per Share	-$0.60	-$1.76	-$2.568M
COMMON SHARES
Basic Shares Outstanding	37.92M shares	38.57M shares	23.37M shares
Diluted Shares Outstanding		38.57M shares	23.37M shares

Balance Sheet

Concept	2022 Q4	2022 Q3	2021 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$266.3M	$323.1M
YoY Change	0.46%
Cash & Equivalents	$71.03M	$127.0M	$0.00
Short-Term Investments	$195.2M	$196.1M
Other Short-Term Assets	$13.65M	$14.27M	$8.460M
YoY Change	43.52%	68.68%
Inventory
Prepaid Expenses	$13.65M	$14.27M	$8.460M
Receivables	$20.96M	$12.04M	$16.14M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$300.9M	$349.4M	$24.60M
YoY Change	3.2%	1320.68%
LONG-TERM ASSETS
Property, Plant & Equipment	$55.74M	$46.65M	$33.75M
YoY Change	59.64%	38.21%
Goodwill	$12.06M	$12.06M	$12.06M
YoY Change	0.0%	0.0%
Intangibles	$7.302M	$7.479M	$11.01M
YoY Change	-26.18%	-32.06%
Long-Term Investments	$1.414M	$1.407M
YoY Change	-98.54%
Other Assets	$38.39M	$38.28M	$6.237M
YoY Change	-0.52%	513.71%
Total Long-Term Assets	$355.8M	$359.3M	$168.4M
YoY Change	-24.0%	113.42%
TOTAL ASSETS
Total Short-Term Assets	$300.9M	$349.4M	$24.60M
Total Long-Term Assets	$355.8M	$359.3M	$168.4M
Total Assets	$656.7M	$708.7M	$193.0M
YoY Change	-13.56%	267.3%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$7.208M	$7.983M	$6.197M
YoY Change	19.65%	28.82%
Accrued Expenses	$65.84M	$62.95M	$90.75M
YoY Change	1.02%	-30.63%
Deferred Revenue	$3.000M	$0.00	$0.00
YoY Change	-40.0%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$79.79M	$79.90M	$106.1M
YoY Change	-18.9%	-24.68%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$2.397M	$2.415M	$2.938M
YoY Change	12.96%	-17.8%
Total Long-Term Liabilities	$2.397M	$2.415M	$2.938M
YoY Change	12.96%	-17.8%
TOTAL LIABILITIES
Total Short-Term Liabilities	$79.79M	$79.90M	$106.1M
Total Long-Term Liabilities	$2.397M	$2.415M	$2.938M
Total Liabilities	$346.2M	$385.6M	$251.4M
YoY Change	-13.42%	53.39%
SHAREHOLDERS EQUITY
Retained Earnings	-$293.6M	-$270.5M
YoY Change	643.52%
Common Stock	$4.000K	$4.000K
YoY Change	100.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$310.5M	$323.2M	-$58.41M
YoY Change
Total Liabilities & Shareholders Equity	$656.7M	$708.7M	$193.0M
YoY Change	-13.56%	267.3%

Cashflow Statement

Concept	2022 Q4	2022 Q3	2021 Q3
OPERATING ACTIVITIES
Net Income	-$23.14M	-$67.88M	-$60.00M
YoY Change	-62.05%	13.13%	-16.75%
Depreciation, Depletion And Amortization	$2.325M	$2.377M	$3.500M
YoY Change	-34.23%	-32.09%	45.83%
Cash From Operating Activities	-$55.48M	-$60.93M	-$43.35M
YoY Change	-3.41%	40.55%
INVESTING ACTIVITIES
Capital Expenditures	$3.166M	-$13.42M	-$8.624M
YoY Change	-424.72%	55.59%
Acquisitions
YoY Change
Other Investing Activities	$2.634M	-$68.87M
YoY Change	-92.47%
Cash From Investing Activities	-$532.0K	-$82.29M	-$8.624M
YoY Change	-101.56%	854.2%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	232.0K	175.0K	51.97M
YoY Change	-99.88%	-99.66%
NET CHANGE
Cash From Operating Activities	-55.48M	-60.93M	-43.35M
Cash From Investing Activities	-532.0K	-82.29M	-8.624M
Cash From Financing Activities	232.0K	175.0K	51.97M
Net Change In Cash	-55.78M	-143.0M	0.000
YoY Change	-134.17%
FREE CASH FLOW
Cash From Operating Activities	-$55.48M	-$60.93M	-$43.35M
Capital Expenditures	$3.166M	-$13.42M	-$8.624M
Free Cash Flow	-$58.65M	-$47.51M	-$34.73M
YoY Change	3.86%	36.82%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Entity Central Index Key EntityCentralIndexKey	0001860782
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2021Q3	tsvt	Common Stock Convertible Conversion Ratio CommonStockConvertibleConversionRatio	0.3333
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2022-09-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-40791
	dei	Entity Registrant Name EntityRegistrantName	2seventy bio, Inc.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	86-3658454
	dei	Entity Address Address Line1 EntityAddressAddressLine1	60 Binney Street
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 200
	dei	Entity Address City Or Town EntityAddressCityOrTown	Cambridge
	dei	Entity Address State Or Province EntityAddressStateOrProvince	MA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	2142
	dei	City Area Code CityAreaCode	339
	dei	Local Phone Number LocalPhoneNumber	499-9300
	dei	Security12b Title Security12bTitle	Common Stock, par value $0.0001 per share
	dei	Trading Symbol TradingSymbol	TSVT
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	false
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
	dei	Entity Shell Company EntityShellCompany	false
CY2022Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	37916693	shares
CY2022Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	127021000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	130414000	usd
CY2022Q3	us-gaap	Debt Securities Available For Sale Excluding Accrued Interest Current DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent	196089000	usd
CY2021Q4	us-gaap	Debt Securities Available For Sale Excluding Accrued Interest Current DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent	134643000	usd
CY2022Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	14270000	usd
CY2021Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	9512000	usd
CY2022Q3	us-gaap	Receivables Net Current ReceivablesNetCurrent	12037000	usd
CY2021Q4	us-gaap	Receivables Net Current ReceivablesNetCurrent	16995000	usd
CY2022Q3	us-gaap	Assets Current AssetsCurrent	349417000	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	291564000	usd
CY2022Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	46650000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	34913000	usd
CY2022Q3	us-gaap	Debt Securities Available For Sale Excluding Accrued Interest Noncurrent DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent	1407000	usd
CY2021Q4	us-gaap	Debt Securities Available For Sale Excluding Accrued Interest Noncurrent DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent	97124000	usd
CY2022Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	7479000	usd
CY2021Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	9892000	usd
CY2022Q3	us-gaap	Goodwill Goodwill	12056000	usd
CY2021Q4	us-gaap	Goodwill Goodwill	12056000	usd
CY2022Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	253458000	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	275534000	usd
CY2022Q3	tsvt	Restricted Cash And Other Assets Noncurrent RestrictedCashAndOtherAssetsNoncurrent	38277000	usd
CY2021Q4	tsvt	Restricted Cash And Other Assets Noncurrent RestrictedCashAndOtherAssetsNoncurrent	38592000	usd
CY2022Q3	us-gaap	Assets Assets	708744000	usd
CY2021Q4	us-gaap	Assets Assets	759675000	usd
CY2022Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	7983000	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	6024000	usd
CY2022Q3	tsvt	Accrued Liabilities And Other Liabilities Current AccruedLiabilitiesAndOtherLiabilitiesCurrent	52156000	usd
CY2021Q4	tsvt	Accrued Liabilities And Other Liabilities Current AccruedLiabilitiesAndOtherLiabilitiesCurrent	55410000	usd
CY2022Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	10798000	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	9769000	usd
CY2022Q3	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	0	usd
CY2021Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	5000000	usd
CY2022Q3	tsvt	Collaboration Research Advancement Current CollaborationResearchAdvancementCurrent	8960000	usd
CY2021Q4	tsvt	Collaboration Research Advancement Current CollaborationResearchAdvancementCurrent	22185000	usd
CY2022Q3	us-gaap	Liabilities Current LiabilitiesCurrent	79897000	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	98388000	usd
CY2022Q3	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	40762000	usd
CY2021Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	25762000	usd
CY2022Q3	tsvt	Collaboration Research Advancement Non Current CollaborationResearchAdvancementNonCurrent	0	usd
CY2021Q4	tsvt	Collaboration Research Advancement Non Current CollaborationResearchAdvancementNonCurrent	1135000	usd
CY2022Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	262490000	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	272446000	usd
CY2022Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	2415000	usd
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	2122000	usd
CY2022Q3	us-gaap	Liabilities Liabilities	385564000	usd
CY2021Q4	us-gaap	Liabilities Liabilities	399853000	usd
CY2022Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q3	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2022Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	37912000	shares
CY2022Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	37912000	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	23585000	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	23585000	shares
CY2022Q3	us-gaap	Common Stock Value CommonStockValue	4000	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	2000	usd
CY2022Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	597566000	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	400026000	usd
CY2022Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-3886000	usd
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-712000	usd
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-270504000	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-39494000	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	323180000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	359822000	usd
CY2022Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	708744000	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	759675000	usd
CY2022Q3	us-gaap	Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer	7903000	usd
CY2021Q3	us-gaap	Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer	12337000	usd
	us-gaap	Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer	18425000	usd
	us-gaap	Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer	15527000	usd
CY2022Q3	us-gaap	Revenues Revenues	13408000	usd
CY2021Q3	us-gaap	Revenues Revenues	19257000	usd
	us-gaap	Revenues Revenues	35319000	usd
	us-gaap	Revenues Revenues	38488000	usd
CY2022Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	61739000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	199423000	usd
CY2021Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	61131000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	202394000	usd
CY2022Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	19610000	usd
CY2021Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	22996000	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	60749000	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	69025000	usd
CY2022Q3	tsvt	Income Loss From Collaborative Arrangements IncomeLossFromCollaborativeArrangements	0	usd
CY2021Q3	tsvt	Income Loss From Collaborative Arrangements IncomeLossFromCollaborativeArrangements	0	usd
	tsvt	Income Loss From Collaborative Arrangements IncomeLossFromCollaborativeArrangements	-9642000	usd
	tsvt	Income Loss From Collaborative Arrangements IncomeLossFromCollaborativeArrangements	-10071000	usd
CY2022Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	377000	usd
CY2021Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	320000	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1252000	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	2111000	usd
CY2022Q3	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	50000	usd
CY2021Q3	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	48000	usd
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	181000	usd
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	464000	usd
CY2022Q3	us-gaap	Costs And Expenses CostsAndExpenses	81776000	usd
CY2021Q3	us-gaap	Costs And Expenses CostsAndExpenses	84495000	usd
	us-gaap	Costs And Expenses CostsAndExpenses	271247000	usd
	us-gaap	Costs And Expenses CostsAndExpenses	284065000	usd
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-68368000	usd
CY2021Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-65238000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-235928000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-245577000	usd
CY2022Q3	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	1113000	usd
CY2021Q3	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	0	usd
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	1441000	usd
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	0	usd
CY2022Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-624000	usd
CY2021Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	5237000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	3494000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	14340000	usd
CY2022Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-67879000	usd
CY2021Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-60001000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-230993000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-231237000	usd
CY2022Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2021Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	17000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-67879000	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-60001000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-231010000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-231237000	usd
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.76
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.76
CY2021Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.57
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.57
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-6.67
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-6.67
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-9.90
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-9.90
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	38573000	shares
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	38573000	shares
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	23369000	shares
CY2021Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	23369000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	34612000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	34612000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	23369000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	23369000	shares
CY2022Q3	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	0	usd
	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	0	usd
	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	0	usd
CY2021Q3	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	0	usd
CY2022Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-504000	usd
CY2021Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	0	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-3174000	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	0	usd
CY2022Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-504000	usd
CY2021Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	0	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-3174000	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	0	usd
CY2022Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-68383000	usd
CY2021Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-60001000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-234184000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-231237000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	359822000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	165657000	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	9739000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-2092000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-85711000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	447416000	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1000	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	124000	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	9689000	usd
CY2022Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-578000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-77420000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	378984000	usd
CY2022Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	12207000	usd
CY2022Q3	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	372000	usd
CY2022Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-504000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-67879000	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	323180000	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	74629000	usd
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	17109000	usd
CY2021Q1	tsvt	Transfers From Transfers To Net Parent Investment TransfersFromTransfersToNetParentInvestment	71101000	usd
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-87196000	usd
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	75643000	usd
CY2021Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	11967000	usd
CY2021Q2	tsvt	Transfers From Transfers To Net Parent Investment TransfersFromTransfersToNetParentInvestment	45119000	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-84040000	usd
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	48689000	usd
CY2021Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	11230000	usd
CY2021Q3	tsvt	Transfers From Transfers To Net Parent Investment TransfersFromTransfersToNetParentInvestment	-58325000	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-60001000	usd
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	-58407000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-231010000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-231237000	usd
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	181000	usd
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	464000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	9208000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	12815000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	31635000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	40306000	usd
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-1074000	usd
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-247000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	354000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-3036000	usd
	tsvt	Increase Decrease In Operating Lease Right Of Use Asset IncreaseDecreaseInOperatingLeaseRightOfUseAsset	22076000	usd
	tsvt	Increase Decrease In Operating Lease Right Of Use Asset IncreaseDecreaseInOperatingLeaseRightOfUseAsset	11146000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	422000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	607000	usd
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-1598000	usd
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	32066000	usd
CY2022Q3	tsvt	Interest Receivable Write Off InterestReceivableWriteOff	0	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-8927000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-13305000	usd
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	10000000	usd
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-820000	usd
	tsvt	Increase Decrease In Collaboration Research Advancement IncreaseDecreaseInCollaborationResearchAdvancement	14361000	usd
	tsvt	Increase Decrease In Collaboration Research Advancement IncreaseDecreaseInCollaborationResearchAdvancement	4920000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-181654000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-149595000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	19676000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	10600000	usd
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	115692000	usd
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	0	usd
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	147597000	usd
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	0	usd
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	0	usd
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	8000000	usd
	tsvt	Interest Receivable Write Off InterestReceivableWriteOff	0	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	12229000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-18600000	usd
	us-gaap	Proceeds From Contributions From Parent ProceedsFromContributionsFromParent	0	usd
	us-gaap	Proceeds From Contributions From Parent ProceedsFromContributionsFromParent	168195000	usd
	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	165531000	usd
	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	0	usd
	tsvt	Proceeds From Stock Options Exercised And Stock Plans ProceedsFromStockOptionsExercisedAndStockPlans	466000	usd
	tsvt	Proceeds From Stock Options Exercised And Stock Plans ProceedsFromStockOptionsExercisedAndStockPlans	0	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	165997000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	168195000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-3428000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	0	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	163266000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	0	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	159838000	usd
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	0	usd
CY2022Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	127021000	usd
CY2021Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	0	usd
CY2022Q3	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	32817000	usd
CY2021Q3	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	0	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	159838000	usd
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	0	usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	2828000	usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	321000	usd
	tsvt	Noncash Or Part Noncash Transfer To Net Parent Investment NoncashOrPartNoncashTransferToNetParentInvestment	0	usd
	tsvt	Noncash Or Part Noncash Transfer To Net Parent Investment NoncashOrPartNoncashTransferToNetParentInvestment	110300000	usd
	us-gaap	Nature Of Operations NatureOfOperations	Description of the business<div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2seventy bio, Inc. (the “Company” or “2seventy bio”) was incorporated in Delaware on April 26, 2021 and is a cell and gene therapy company focused on the research, development, and commercialization of transformative treatments for cancer. The Company’s approach combines its expertise in T cell engineering technology and lentiviral vector gene delivery approaches, experience in research, development, and manufacturing of cell therapies and a suite of technologies that can be selectively deployed to develop highly innovative, targeted cellular therapies for patients with cancer. The Company is advancing multiple preclinical and clinical programs in oncology and, together with Bristol-Myers Squibb (“BMS”), delivering the first U.S. Food and Drug Administration (“FDA”)-approved CAR T therapy in multiple myeloma, ABECMA (idecabtagene vicleucel, or ide-cel), to patients in the United States. Please refer to Note 9, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative arrangements and strategic partnerships </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for further discussion of the collaboration with BMS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2seventy bio Securities Corporation is a wholly-owned subsidiary of the Company which was incorporated in Massachusetts on December 13, 2021 and was granted securities corporation status in Massachusetts for the 2021 tax year. 2seventy bio Securities Corporation has no employees.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The separation from bluebird bio, Inc.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, bluebird bio, Inc. (“bluebird bio”) announced its plans to separate its oncology portfolio and programs from its severe genetic disease portfolio and programs, and spin off its oncology portfolio and programs into a separate, publicly traded company. In furtherance of this plan, on September 30, 2021, bluebird bio’s board of directors approved the distribution of all of the issued and outstanding shares of 2seventy bio common stock on the basis of one share of 2seventy bio common stock for every three shares of bluebird bio common stock issued and outstanding on October 19, 2021, the record date for the distribution. As a result of the distribution, which occurred on November 4, 2021, 2seventy bio became an independent, publicly traded company.</span></div><div style="margin-bottom:12pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 3, 2021, the Company also entered into a separation agreement with bluebird bio, which is referred to in this quarterly report as the “Separation Agreement”, as well as various other agreements with bluebird bio, including a tax matters agreement, an employee matters agreement, an intellectual property license agreement, a transition services agreement under which 2seventy bio temporarily receives certain services from bluebird bio, and a second transition services agreement under which 2seventy bio temporarily provides certain services to bluebird bio. These agreements also govern certain of 2seventy bio’s relationships with bluebird bio after the separation. For additional information regarding the Separation Agreement and the other related agreements, refer to Note 13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Related-party transactions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and the section captioned “Part III. Item 13. Certain Relationships and Related Transactions, and Director Independence,” included in our Annual Report on Form 10-K, which was filed with the SEC on March 22, 2022.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Going concern</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with Accounting Standards Codification 205-40, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Going Concern</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about its ability to continue as a going concern within one year after the date that the condensed consolidated and combined financial statements are issued. The Company has incurred losses and has experienced negative operating cash flows for all historical periods presented. During the nine months ended September 30, 2022, the Company incurred a net loss of $231.0 million and used $181.7 million of cash in operations. The Company expects to continue to generate operating losses and negative operating cash flows for the next few years. The Company's continued operations are dependent on its ability to raise additional funding. </span></div>As of September 30, 2022, the Company had cash, cash equivalents, and marketable securities of $324.5 million. The Company expects that its cash, cash equivalents, and marketable securities will be sufficient to fund current planned operations for at least the next twelve months from the date of issuance of these financial statements. The Company intends to pursue additional cash resources through a combination of public or private equity offerings, debt financings, collaborations, strategic alliances or licensing arrangements with third parties. There can be no assurance that such financing will be available in sufficient amounts or on acceptable terms, if at all, and some could be dilutive to existing stockholders. If the Company is unable to obtain additional funding on a timely basis, it may be forced to significantly curtail, delay, or discontinue one or more of its planned research or development programs or be unable to expand its operations.
	us-gaap	Net Income Loss NetIncomeLoss	-231000000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-181700000	usd
CY2022Q3	tsvt	Cash Cash Equivalents And Marketable Securities CashCashEquivalentsAndMarketableSecurities	324500000	usd
	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of estimates</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts in the financial statements and accompanying notes. Actual results could materially differ from those estimates. Management considers many factors in selecting appropriate financial accounting policies and controls, and in developing the estimates and assumptions that are used in the preparation of these financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including: expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">future outcomes and management must select an amount that falls within that range of reasonable estimates. This process may result in actual results differing materially from those estimated amounts used in the preparation of the financial statements.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimates and judgments are used in the following areas, among others: allocations of revenue, expenses, assets and liabilities from bluebird bio's historical consolidated financial statements to the Company for periods prior to the separation, future undiscounted cash flows and subsequent fair value estimates used to assess potential and measure any impairment of long-lived assets, including goodwill and intangible assets, the measurement of right-of-use assets and lease liabilities, contingent consideration, stock-based compensation expense, accrued expenses, income taxes, and the assessment of the Company's ability to fund its operations for at least the next twelve months from the date of issuance of these financial statements. In addition, estimates and judgments are used in the Company’s accounting for its revenue-generating arrangements, in particular as it relates to determining the stand-alone selling price of performance obligations, evaluating whether an option to acquire additional goods and services represents a material right, estimating the total transaction price, including estimating variable consideration and the probability of achieving future potential development and regulatory milestones, assessing the period of performance over which revenue may be recognized, and accounting for modifications to revenue-generating arrangements.</span></div>
CY2022Q3	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	200395000	usd
CY2022Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	usd
CY2022Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	2899000	usd
CY2022Q3	us-gaap	Debt Securities Available For Sale Excluding Accrued Interest DebtSecuritiesAvailableForSaleExcludingAccruedInterest	197496000	usd
CY2021Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	232332000	usd
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	usd
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	565000	usd
CY2021Q4	us-gaap	Debt Securities Available For Sale Excluding Accrued Interest DebtSecuritiesAvailableForSaleExcludingAccruedInterest	231767000	usd
CY2022Q3	us-gaap	Interest Receivable InterestReceivable	200000	usd
CY2021Q4	us-gaap	Interest Receivable InterestReceivable	400000	usd
	tsvt	Interest Receivable Write Off InterestReceivableWriteOff	0	usd
CY2021Q3	tsvt	Interest Receivable Write Off InterestReceivableWriteOff	0	usd
CY2022Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	92340000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	74991000	usd
CY2022Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	45690000	usd
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	40078000	usd
CY2022Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	46650000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	34913000	usd
CY2022Q3	tsvt	Accrued Manufacturing Costs Current AccruedManufacturingCostsCurrent	15516000	usd
CY2021Q4	tsvt	Accrued Manufacturing Costs Current AccruedManufacturingCostsCurrent	5459000	usd
CY2022Q3	tsvt	Accrued Collaboration Research Costs Current AccruedCollaborationResearchCostsCurrent	9889000	usd
CY2021Q4	tsvt	Accrued Collaboration Research Costs Current AccruedCollaborationResearchCostsCurrent	2576000	usd
CY2022Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	9657000	usd
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	24655000	usd
CY2022Q3	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	7828000	usd
CY2021Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	6768000	usd
CY2022Q3	tsvt	Accrued Clinical And Contract Research Organization Costs Current AccruedClinicalAndContractResearchOrganizationCostsCurrent	2285000	usd
CY2021Q4	tsvt	Accrued Clinical And Contract Research Organization Costs Current AccruedClinicalAndContractResearchOrganizationCostsCurrent	3229000	usd
CY2022Q3	tsvt	Accrued Property Plant And Equipment Current AccruedPropertyPlantAndEquipmentCurrent	683000	usd
CY2021Q4	tsvt	Accrued Property Plant And Equipment Current AccruedPropertyPlantAndEquipmentCurrent	2241000	usd
CY2022Q3	tsvt	Accrued Separation Related Costs Current AccruedSeparationRelatedCostsCurrent	405000	usd
CY2021Q4	tsvt	Accrued Separation Related Costs Current AccruedSeparationRelatedCostsCurrent	762000	usd
CY2022Q3	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	349000	usd
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1688000	usd
CY2022Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	5544000	usd
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	8032000	usd
CY2022Q3	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	52156000	usd
CY2021Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	55410000	usd
CY2022Q3	tsvt	Number Of Performance Obligations NumberOfPerformanceObligations	2	performance_obligation
CY2018Q3	tsvt	Number Of Accounting Units NumberOfAccountingUnits	2	accounting_unit
CY2022Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	12207000	usd
CY2021Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	11230000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	31635000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	40306000	usd
CY2022Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	12207000	usd
CY2021Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	11230000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	31635000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	40306000	usd
CY2021Q4	tsvt	Number Of Transition Services Agreements NumberOfTransitionServicesAgreements	2	agreement
CY2021Q4	tsvt	Transition Services Agreement Initial Term TransitionServicesAgreementInitialTerm	P2Y
CY2022Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3969000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3969000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	0	shares
CY2021Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	0	shares

Files In Submission

Name	View Source	Status
tsvt-20220930_cal.xml	Edgar Link	unprocessable
0001860782-22-000067-index-headers.html	Edgar Link	pending
0001860782-22-000067-index.html	Edgar Link	pending
0001860782-22-000067.txt	Edgar Link	pending
0001860782-22-000067-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
tsvt-20220930.htm	Edgar Link	pending
tsvt-20220930.xsd	Edgar Link	pending
tsvt-q310xqex311leschly1.htm	Edgar Link	pending
tsvt-q310xqexhibit312baird1.htm	Edgar Link	pending
tsvt-q3202210xqexhibit3211.htm	Edgar Link	pending
tsvt-20220930_lab.xml	Edgar Link	unprocessable
tsvt-20220930_def.xml	Edgar Link	unprocessable
tsvt-20220930_pre.xml	Edgar Link	unprocessable
tsvt-20220930_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$TSVT
2seventy bio, Inc. Stock $tsvt

2022 Q4 Form 10-Q Financial Statement

#000186078222000067 Filed on November 07, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TSVT 2seventy bio, Inc. Stock $tsvt

2022 Q4 Form 10-Q Financial Statement

#000186078222000067 Filed on November 07, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TSVT
2seventy bio, Inc. Stock $tsvt